The invention relates to a topical nanoformulation (SkinGuard53-VitD) which combines MANIO, a mutant p53 reactivator agent, with Vitamin D, an activity enhancer. SkinGuard53-VitD exhibits a potent protective effect against UVA- and UVB-induced skin cancer, enhancing survival, DNA repair, and antioxidante response, while reducing apoptosis, DNA damage, inflammation, and genotoxicity, also presenting a safe toxicological profile. It also preserves dermal matrix integrity, inhibiting collagen degradation.
The rising incidence of skin cancer highlights the urgent need for effective preventive strategies. While p53-targeting agents show great promise, their application in skin cancer prevention remains unexplored
This is a best-in-class p53-targeting agent (MANIO) with enhanced activity (in combination with Vitamin D) for the effective prevention of skin carcinogenesis. It has potent protective activity against UVA- and UVB-induced skin cancer and safe toxicological profile, in mouse and human skin.
Combination with sunscreens to prevent skin cancer; Potential for combination with other therapeutic agents to treat skin cancer.
